Inflammatory Bowel Disease News

An abundance of Faecalibacterium prausnitzii or Roseburia hominis may predict the effectiveness of high-dose thiamine treatment to alleviate chronic fatigue in quiescent inflammatory bowel disease, according to research.

The treatment sequence of vedolizumab to adalimumab resulted in the lowest overall incidences of hospitalization and surgery in both Crohn’s disease and ulcerative colitis compared with other biologic treatment sequences, research showed.

No significant differences were reported in clinical response at day 7 between 5 mg/kg and 10 kg/kg doses of infliximab in acute severe ulcerative colitis, nor were there differences in intensified, accelerated or standard dosing at month 3.

Early endoscopic improvement after Skyrizi induction was associated with fewer Crohn’s disease-related hospitalizations and surgeries through 52 weeks of maintenance in patients with moderately to severely active disease, research showed.

The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of patients with moderately to severely active ulcerative colitis, according to a company release.

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

Initiation of biological therapy within the first year of Crohn’s disease diagnosis was associated with a higher rate of transmural healing, as well as decreased risk for bowel damage progression, surgery and therapy escalation.

Long-term filgotinib induced and maintained symptomatic remission and improved health-related quality of life in ulcerative colitis, with no new safety signals reported, according to interim analysis of the SELECTION extension study.

Multidisciplinary care is key when managing patients with pregnancy-related gastrointestinal and liver diseases, with a “paramount goal” of keeping both the patient and the fetus safe, according to an AGA clinical practice update.

Although Skyrizi was noninferior to Stelara in clinical remission at week 24, it was superior in endoscopic remission at week 48 in patients with moderate to severe Crohn’s disease, according to data from the SEQUENCE trial.